Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004176 · ClinicalTrials.gov registry record · Phase 2
Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00004176 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 34 participants.
The verdict
NCT00004176, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase II trial to study the effectiveness of amifostine plus chemotherapy and radiation therapy in treating patients who have limited-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG etoposide
- RADIATION radiation therapy
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1998-10 |
| Est. Completion | 2001-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004176
The ClinicalTrials.gov registry entry for NCT00004176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00004176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004176 about?
NCT00004176 is a clinical study titled "Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PUR...
What is the current status of trial NCT00004176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 1998-10. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00004176?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00004176?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.